ProQR rises after AI drug discovery tie-up with Ginkgo Bioworks

Shares of biotech firm ProQR Therapeutics PRQR.O rise 5.8% to $1.80 premarket

Co says it partnered with Ginkgo Bioworks DNA.N to speed up drug discovery using artificial intelligence

Partnership gives ProQR access to Ginkgo’s automated lab platform, Nebula, to generate large amounts of experimental data more quickly, co says

Co says the deal includes a strategic equity investment by Ginkgo, without disclosing financial terms

ProQR aims to file a clinical trial application for its first AI‑discovered drug candidate by mid‑2026, with early patient data expected by year‑end - PRQR

Co says it will outline its AI strategy and pipeline at a virtual investor event later on Tuesday

Shares of Ginkgo Bioworks up 5% to $7.15 premarket

As of last close, PRQR down ~19% YTD, DNA down ~18% YTD